Brains Bioceutical Corp. announced that it has entered into a definitive business combination agreement with Armada Acquisition Corp. III (Nasdaq: AACI) in a proposed $750 million transaction. Lucosky Brookman LLP serves as U.S. securities counsel to Brains Bioceutical in connection with the transaction.
The proposed combination brings together Brains Bioceutical’s manufacturing capabilities for pharmaceutical-grade cannabinoid active pharmaceutical ingredients (APIs), regulatory expertise, and proprietary and partnered drug development programs. Upon completion of the transaction, the combined company, Brains Therapeutics Corp., is expected to trade on Nasdaq under the ticker symbol “BAPI.”
